Alcon's $200M RxSight partnership aims to recapture IOL market share with adjustable presbyopic lenses. RxSight gets 30% ...
Alcon (NYSE:ALC) and RxSight (Nasdaq:RXST) announced that they entered into a non-exclusive intraocular lens (IOL) ...
Medical Device Network on MSN
Alcon spends up to $200M to co-develop customisable cataract lenses with RxSight
The companies will combine their expertise to develop a ‘tuneable’ presbyopia-correcting intraocular lens (PCIOL) for ...
Alcon and RxSight, Inc have announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting ...
MarketBeat on MSN
RxSight Q2 sales sink 20% as Alcon deal bolsters 2026 outlook
Key Points Interested in RxSight, Inc.? Here are five stocks we like better. RxSight's preliminary Q2 sales fell 20% year ...
Despite near-term headwinds, RxSight has long-term upside from the Alcon royalty partnership, stronger margins and discounted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results